MCAP Stock Overview
A private equity firm specializing in investments in secondary direct, later stage, industry consolidation, add-on acquisitions, growth capital, middle market, mature, turnarounds, buyout.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 0/6 |
Past Performance | 5/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for MCAP from our risk checks.
MedCap AB (publ) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | SEK 601.00 |
52 Week High | SEK 624.00 |
52 Week Low | SEK 247.00 |
Beta | 0.73 |
11 Month Change | 14.91% |
3 Month Change | 40.91% |
1 Year Change | 94.81% |
33 Year Change | 173.18% |
5 Year Change | 396.69% |
Change since IPO | 5,850.50% |
Recent News & Updates
Estimating The Intrinsic Value Of MedCap AB (publ) (STO:MCAP)
Jun 06MedCap AB (publ) (STO:MCAP) Stocks Shoot Up 33% But Its P/E Still Looks Reasonable
May 21Recent updates
Estimating The Intrinsic Value Of MedCap AB (publ) (STO:MCAP)
Jun 06MedCap AB (publ) (STO:MCAP) Stocks Shoot Up 33% But Its P/E Still Looks Reasonable
May 21Should You Be Adding MedCap (STO:MCAP) To Your Watchlist Today?
May 04MedCap AB (publ)'s (STO:MCAP) P/E Is Still On The Mark Following 25% Share Price Bounce
Feb 15Is Now The Time To Put MedCap (STO:MCAP) On Your Watchlist?
Dec 21Do MedCap's (STO:MCAP) Earnings Warrant Your Attention?
May 06These 4 Measures Indicate That MedCap (STO:MCAP) Is Using Debt Safely
Nov 23We Ran A Stock Scan For Earnings Growth And MedCap (STO:MCAP) Passed With Ease
Sep 21Does MedCap (STO:MCAP) Deserve A Spot On Your Watchlist?
Apr 29MedCap (STO:MCAP) Seems To Use Debt Rather Sparingly
Feb 01Should You Be Adding MedCap (STO:MCAP) To Your Watchlist Today?
Aug 03Does MedCap (STO:MCAP) Have A Healthy Balance Sheet?
May 27Here's Why I Think MedCap (STO:MCAP) Is An Interesting Stock
Apr 07Imagine Holding MedCap (STO:MCAP) Shares While The Price Zoomed 558% Higher
Mar 15Have Insiders Been Selling MedCap AB (publ) (STO:MCAP) Shares?
Feb 26MedCap (STO:MCAP) Could Easily Take On More Debt
Feb 08Declining Stock and Solid Fundamentals: Is The Market Wrong About MedCap AB (publ) (STO:MCAP)?
Jan 22Should You Be Adding MedCap (STO:MCAP) To Your Watchlist Today?
Jan 07MedCap (STO:MCAP) Is Growing Earnings But Are They A Good Guide?
Dec 22If You Had Bought MedCap (STO:MCAP) Stock Five Years Ago, You Could Pocket A 663% Gain Today
Dec 08Are Insiders Selling MedCap AB (publ) (STO:MCAP) Stock?
Nov 23Shareholder Returns
MCAP | SE Life Sciences | SE Market | |
---|---|---|---|
7D | 13.8% | 0.5% | -0.2% |
1Y | 94.8% | 51.8% | 14.5% |
Return vs Industry: MCAP exceeded the Swedish Life Sciences industry which returned 51.8% over the past year.
Return vs Market: MCAP exceeded the Swedish Market which returned 14.5% over the past year.
Price Volatility
MCAP volatility | |
---|---|
MCAP Average Weekly Movement | 7.3% |
Life Sciences Industry Average Movement | 8.2% |
Market Average Movement | 5.7% |
10% most volatile stocks in SE Market | 12.2% |
10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: MCAP's share price has been volatile over the past 3 months.
Volatility Over Time: MCAP's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2001 | 530 | Anders Dahlberg | medcap.se/en/ |
MedCap AB (publ) is a private equity firm specializing in investments in secondary direct, later stage, industry consolidation, add-on acquisitions, growth capital, middle market, mature, turnarounds, buyout. It prefers to invest in healthcare equipment and services, biotechnology, life sciences, pharmaceuticals, med tech and assistive tech companies. The firm prefers to invest in small to medium size companies that are not listed on the stock exchange and are based in Nordic region and Northern Europe.
MedCap AB (publ) Fundamentals Summary
MCAP fundamental statistics | |
---|---|
Market cap | SEK 8.90b |
Earnings (TTM) | SEK 213.50m |
Revenue (TTM) | SEK 1.75b |
41.7x
P/E Ratio5.1x
P/S RatioIs MCAP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MCAP income statement (TTM) | |
---|---|
Revenue | SEK 1.75b |
Cost of Revenue | SEK 709.00m |
Gross Profit | SEK 1.04b |
Other Expenses | SEK 830.30m |
Earnings | SEK 213.50m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 25, 2024
Earnings per share (EPS) | 14.42 |
Gross Margin | 59.55% |
Net Profit Margin | 12.18% |
Debt/Equity Ratio | 8.2% |
How did MCAP perform over the long term?
See historical performance and comparison